No connection

Search Results

ARCT vs INGN

ARCT
Arcturus Therapeutics Holdings Inc.
BEARISH
Price
$6.68
Market Cap
$189.9M
Sector
Healthcare
AI Confidence
85%
INGN
Inogen, Inc.
BEARISH
Price
$6.33
Market Cap
$172.4M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ARCT
--
INGN
--
Forward P/E
ARCT
-1.61
INGN
-20.42
P/B Ratio
ARCT
0.89
INGN
0.9
P/S Ratio
ARCT
2.31
INGN
0.49
EV/EBITDA
ARCT
0.22
INGN
-7.36

Profitability

Gross Margin
ARCT
-36.79%
INGN
44.24%
Operating Margin
ARCT
-435.06%
INGN
-12.21%
Profit Margin
ARCT
-80.19%
INGN
-6.52%
ROE
ARCT
-28.92%
INGN
-12.43%
ROA
ARCT
-15.5%
INGN
-6.35%

Growth

Revenue Growth
ARCT
-68.4%
INGN
2.0%
Earnings Growth
ARCT
--
INGN
--

Financial Health

Debt/Equity
ARCT
0.12
INGN
0.09
Current Ratio
ARCT
6.64
INGN
3.12
Quick Ratio
ARCT
6.5
INGN
2.52

Dividends

Dividend Yield
ARCT
--
INGN
--
Payout Ratio
ARCT
0.0%
INGN
0.0%

AI Verdict

ARCT BEARISH

ARCT exhibits severe financial distress despite a modest insider sentiment score and analyst buy consensus. The Piotroski F-Score of 0/9 signals extreme financial weakness, with no positive indicators in profitability, cash flow, or leverage management. The Altman Z-Score is unavailable, but the company's negative margins, declining revenue, and negative earnings suggest high distress risk. While the stock trades below its 52-week high, its 5-year decline of 87.2% and persistent losses underscore deep operational challenges. The Graham Number and intrinsic value are unavailable, indicating no reliable fundamental floor, and the current price reflects speculative expectations rather than sustainable value.

Strengths
Analyst consensus is 'buy' with a target price of $23.44, implying significant upside potential
Insider sentiment is moderately positive at 40/100, suggesting some confidence in long-term prospects
Strong liquidity with a current ratio of 6.64 and quick ratio of 6.50, indicating robust short-term financial health
Risks
Piotroski F-Score of 0/9 indicates extreme financial instability and operational failure across all nine criteria
Revenue declined 68.4% YoY, signaling a severe contraction in business activity
Negative profit margins across all measures: -80.19% (net), -435.06% (operating), -36.79% (gross)
INGN BEARISH

INGN exhibits severe operational distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a significant deterioration in financial health. While the company maintains a strong liquidity position with a Current Ratio of 3.12 and very low debt (D/E 0.09), it is unable to translate this into profitability, as evidenced by negative operating margins and stagnant revenue growth of 2%. There is a stark disconnect between the 'Strong Buy' analyst consensus and the fundamental reality of a 5-year price collapse of 88.6%. The stock currently presents as a classic value trap, trading below book value but lacking the growth catalysts necessary for a reversal.

Strengths
Very low leverage (Debt/Equity 0.09)
Strong short-term liquidity (Current Ratio 3.12)
Healthy Gross Margin (44.24%)
Risks
Critical operational failure (Piotroski F-Score 1/9)
Stagnant top-line growth (YoY Revenue Growth 2.00%)
Persistent net losses and negative ROE (-12.43%)

Compare Another Pair

ARCT vs INGN: Head-to-Head Comparison

This page compares Arcturus Therapeutics Holdings Inc. (ARCT) and Inogen, Inc. (INGN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile